SPC-069/SPX-001 – Respiratory Infection treatment candidate
SpectrumX is progressing the first novel drug candidate in its pipeline. SPX-001 is currently in the clinical trial approval process for a Phase Ib clinical trial. SPX-001 is an inhaled treatment, with the drug candidate taken via a nebuliser which delivers the unique chemistry designed specifically for the respiratory system. This allows for a direct mode of action against viral particles both in the sinuses and lungs.
![](https://www.spectrumx.com/wp-content/uploads/2022/10/close-up-hand-holding-tube-min-1024x576.jpg)
Initial trials will focus on the treatment on influenza which globally is responsible for 518,000 deaths per year.
Due to the positively non-selective mode of action of the underlying active ingredient (HOCl), SpectrumX plans in time to undertake clinical trials for a range of widespread respiratory infections. In preparation for a Phase Ib Challenge Trial, SPC-069 (the active pharmaceutical ingredient in SPX-001) was tested in vitro against Influenza A (H1N1), Influenza A (H3N2) and Influenza B (Victoria Lineage), showing 100% eradication in 60 seconds.
![](https://www.spectrumx.com/wp-content/uploads/2023/01/chart_influenza-a-h1n1.jpg)
![](https://www.spectrumx.com/wp-content/uploads/2023/01/chart-influenza-A.jpg)
![](https://www.spectrumx.com/wp-content/uploads/2023/01/chart-influenza-b.jpg)
![](https://www.spectrumx.com/wp-content/uploads/2023/01/chart_alpha.jpg)
![](https://www.spectrumx.com/wp-content/uploads/2023/01/chart_delta.jpg)
![](https://www.spectrumx.com/wp-content/uploads/2023/01/chart_omicron-1.jpg)
![](https://www.spectrumx.com/wp-content/uploads/2023/01/chart_wuhan.jpg)